Navigating Drug Approvals

🚨 𝗕𝗿𝗲𝗮𝗸𝗶𝗻𝗴 𝗻𝗲𝘄𝘀 𝗳𝗿𝗼𝗺 𝗙𝗗𝗔 Drug approval no longer starts with a trial. It starts with a mechanism. The FDA has introduced the “𝗽𝗹𝗮𝘂𝘀𝗶𝗯𝗹𝗲 𝗺𝗲𝗰𝗵𝗮𝗻𝗶𝘀𝗺” 𝗽𝗮𝘁𝗵𝘄𝗮𝘆: a new route to approve bespoke therapies when classic trials are impossible.  Think N-of-1 gene editing for ultra-rare, often fatal childhood diseases. 𝟱 𝗲𝗹𝗲𝗺𝗲𝗻𝘁𝘀 𝘁𝗵𝗲 𝗙𝗗𝗔 𝘄𝗮𝗻𝘁𝘀 𝘁𝗼 𝘀𝗲𝗲 𝗯𝗲𝗳𝗼𝗿𝗲 𝗮𝗽𝗽𝗿𝗼𝘃𝗮𝗹 1️⃣ 𝗖𝗹𝗲𝗮𝗿 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗰𝗮𝘂𝘀𝗲 A single, well-defined genetic or molecular defect driving the disease. 2️⃣ 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 𝗱𝗲𝘀𝗶𝗴𝗻𝗲𝗱 𝘁𝗼 𝗳𝗶𝘅 𝘁𝗵𝗮𝘁 𝗱𝗲𝗳𝗲𝗰𝘁 The product must target the precise mechanism: the edit, splice, or RNA change that corrects the biology. 3️⃣ 𝗪𝗲𝗹𝗹-𝘂𝗻𝗱𝗲𝗿𝘀𝘁𝗼𝗼𝗱 𝗻𝗮𝘁𝘂𝗿𝗮𝗹 𝗵𝗶𝘀𝘁𝗼𝗿𝘆 Strong historical data showing how the disease progresses without treatment, so real benefit is clear. 4️⃣ 𝗘𝘃𝗶𝗱𝗲𝗻𝗰𝗲 𝗼𝗳 𝘁𝗮𝗿𝗴𝗲𝘁 𝗲𝗻𝗴𝗮𝗴𝗲𝗺𝗲𝗻𝘁 Proof the therapy does what it’s meant to do, through biomarkers, biopsies, or validated non-animal models. 5️⃣ 𝗠𝗲𝗮𝗻𝗶𝗻𝗴𝗳𝘂𝗹 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗯𝗲𝗻𝗲𝗳𝗶𝘁 Improvements strong enough that they cannot be dismissed as noise. A single patient can serve as their own control. If a platform shows success in several different patients, even with unique bespoke edits, the FDA can move toward platform-level authorization, not just case-by-case exemptions. 👉 𝗪𝗵𝘆 𝘁𝗵𝗶𝘀 𝗺𝗮𝘁𝘁𝗲𝗿𝘀 𝗳𝗼𝗿 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀  For families facing ultra-rare genetic diseases, the old logic was brutal: too rare for trials → no drug → no options. This pathway changes that:  • From “too rare to study” → “biologically defined and actionable.”  • From isolated compassionate-use miracles → a structured regulatory route.  • From decade-long timelines → months from design to first dosing in the most urgent pediatric cases. And it does not end at approval:  • Long-term real-world evidence  • Ongoing monitoring for off-target edits, immune issues, developmental risks  • Registries to track durability and outcomes 👉 𝗪𝗵𝗼 𝗯𝗲𝗻𝗲𝗳𝗶𝘁𝘀 𝗳𝗶𝗿𝘀𝘁?  • Infants with lethal monogenic diseases  • Ultra-rare disorders with a single known driver mutation  • Small, genetically defined subsets in oncology and immunology 𝗜𝘁’𝘀 𝗮 𝗯𝗶𝗼𝗹𝗼𝗴𝘆-𝗳𝗶𝗿𝘀𝘁, 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺-𝗯𝗮𝘀𝗲𝗱 𝗮𝗽𝗽𝗿𝗼𝗮𝗰𝗵 𝗯𝘂𝗶𝗹𝘁 𝗳𝗼𝗿 𝗰𝗼𝗻𝗱𝗶𝘁𝗶𝗼𝗻𝘀 𝘄𝗵𝗲𝗿𝗲 𝗹𝗮𝗿𝗴𝗲 𝘁𝗿𝗶𝗮𝗹𝘀 𝘄𝗶𝗹𝗹 𝗻𝗲𝘃𝗲𝗿 𝗯𝗲 𝗽𝗼𝘀𝘀𝗶𝗯𝗹𝗲. It’s a design guide for how to build your next platform and IND package. Because for many families, this is the first time “𝘆𝗼𝘂𝗿 𝗯𝗶𝗼𝗹𝗼𝗴𝘆 𝗶𝘀 𝘂𝗻𝗶𝗾𝘂𝗲” doesn’t automatically mean “𝘆𝗼𝘂’𝗿𝗲 𝗼𝗻 𝘆𝗼𝘂𝗿 𝗼𝘄𝗻.”

FDA rolls out generative AI tool ‘Elsa’ to speed up reviews and streamline regulatory tasks >> 💊The FDA is rolling out Elsa, a secure generative AI tool that helps staff accelerate clinical reviews, summarize adverse events, compare drug labels, and even generate code for internal systems 💊Elsa is built on a large language model and housed in a high-security GovCloud environment, ensuring sensitive regulatory data stays in-house and not trained on by external models 💊Early results from pilot testing with FDA scientific reviewers were positive, leading to the accelerated, under-budget deployment across all centers (original target launch date was June 30th) 💊Elsa’s debut is seen as the first step in a broader AI integration strategy that will expand to include advanced analytics and further generative AI use cases 💊FDA leadership is positioning AI as a lever to boost performance without compromising scientific rigor, describing Elsa as a tool that “enhances and optimizes the potential of every employee.” 💊Elsa launches amid a proposed 4% FDA budget cut and loss of up to 3,500 staff, potentially helping offset pressure on review timelines #digitalhealth #ai #pharma

Earlier this month, the U.S. Food & Drug Administration announced a major step toward integrating Generative AI across the agency — a move that could reshape how new medicines, devices, and diagnostics are evaluated.   The potential benefits are compelling. AI could streamline parts of the review process, reduce administrative burden, and enable faster, more consistent decision-making. For example, the FDA will use its GenAI tool, Elsa, to accelerate clinical protocol reviews, compare drug labels, summarize adverse events, identify high-priority inspection targets, and more. These applications could play a meaningful role in supporting the FDA’s mission of bringing safe, effective medicines to patients – potentially faster and more efficiently. Of course, with this opportunity comes responsibility. The agency oversees some of the most sensitive data and high-stakes decisions in healthcare. As AI becomes more embedded in regulatory workflows, a few principles will be critical: ◆ 𝗔𝗜 𝘀𝗵𝗼𝘂𝗹𝗱 𝗿𝗮𝗶𝘀𝗲 𝘁𝗵𝗲 𝗯𝗮𝗿. It should help ‘supercharge’ reviewers and strengthen the quality and consistency of reviews. ◆ 𝗛𝘂𝗺𝗮𝗻 𝗼𝘃𝗲𝗿𝘀𝗶𝗴𝗵𝘁 𝗶𝘀 𝗲𝘀𝘀𝗲𝗻𝘁𝗶𝗮𝗹. AI can and should support decision-making, but experienced reviewers will still need to be at the helm. ◆ 𝗧𝗿𝗮𝗻𝘀𝗽𝗮𝗿𝗲𝗻𝗰𝘆 𝗯𝘂𝗶𝗹𝗱𝘀 𝘁𝗿𝘂𝘀𝘁. Clear, proactive communication about how tools are trained and used will help bolster confidence across industry and the public. ◆ 𝗗𝗮𝘁𝗮 𝘀𝗲𝗰𝘂𝗿𝗶𝘁𝘆 𝗺𝘂𝘀𝘁 𝗯𝗲 𝘂𝗻𝗰𝗼𝗺𝗽𝗿𝗼𝗺𝗶𝘀𝗶𝗻𝗴. Protecting proprietary and patient-related information, of course, has to remain a top priority. It’s encouraging to see the FDA taking such a forward-looking, measured approach — one that mirrors how many of us in the field, including our team at Recursion, are approaching AI: test, learn, improve, and scale. This is both an exciting and consequential moment for the industry. Done right, AI can help supercharge the regulatory review process while upholding the scientific rigor and trust that define the FDA. I’ll be watching closely — and optimistically — to see how this evolves over the months ahead! #GenerativeAI #ResponsibleAI #FDANews #RegulatoryAffairs #DrugDevelopment

🚨 74% of FDA rejections were avoidable. We analysed all 202 Complete Response Letters the FDA just released - and here’s the real problem: - It’s not just where your drug is made. - It’s who’s building it. When the FDA made 202 Complete Response Letters public last week, we commissioned a full-scale deep data analysis - tagging every document by failure type, modality, and functional root cause. 💥 The results are clear: - Most rejections weren’t scientific. - They were operational. The most common patterns? 🔻 No internal Head of CMC - outsourced too early 🔻 INDs drafted without Regulatory leadership in place 🔻 GMP build-outs led by consultants, not accountable site heads 🔻 QA/QMS left until post-PPQ 🔻 No plan to qualify dual-source vendors These gaps don’t show up in press releases. But they do show up in FDA inspection reports, CRLs… …or when an investor starts asking REAL diligence questions. And those questions are changing fast: • “Who wrote your Quality System?” • “Where are your vectors made - and how exposed is the supply chain?” • “Do you have anyone who’s led a successful BLA/NDA?” • “Who’s preparing your site for pre-approval inspection?” - In 2021, these questions came up after the raise. - In 2025, they’re being asked before the term sheet. 📥 Want the data? Drop “CRL” in the comments and I’ll send the full PDF: 𝐓𝐡𝐞 𝐟𝐢𝐫𝐬𝐭-𝐞𝐯𝐞𝐫 𝐚𝐧𝐚𝐥𝐲𝐬𝐢𝐬 𝐨𝐟 𝐚𝐥𝐥 𝟐𝟎𝟐 𝐅𝐃𝐀 𝐫𝐞𝐣𝐞𝐜𝐭𝐢𝐨𝐧 𝐥𝐞𝐭𝐭𝐞𝐫𝐬 - with breakdowns for Regulatory, CMC, QA, and Clinical teams. This is what every biotech operator, board, and investor should be reviewing right now. #FDA #CRL #Biotech #RegulatoryAffairs #CMC #QA #ExecutiveHiring #PrivateEquity #VentureCapital

“The FDA receives around 22,000 medical device premarket submissions each year. For 510(k) submissions, about 30% are refused for administrative reasons (Refuse to Accept) before full review” That's thousands of MedTech companies facing costly delays and rework and in today's economic climate, those delays can be catastrophic to your runway. I was speaking with a client yesterday who had spent 18 months developing a breakthrough cardiac monitoring device. Their submission was rejected due to insufficient clinical evidence documentation, a problem that could have been identified months earlier. This happens far too often in our industry. The most successful MedTech companies I work with don't view regulatory as a hurdle to jump at the end. They build it into their development process from day one. 𝗛𝗲𝗿𝗲 𝗮𝗿𝗲 𝘁𝗵𝗿𝗲𝗲 𝗮𝗽𝗽𝗿𝗼𝗮𝗰𝗵𝗲𝘀 𝘁𝗵𝗮𝘁 𝗰𝗼𝗻𝘀𝗶𝘀𝘁𝗲𝗻𝘁𝗹𝘆 𝘄𝗼𝗿𝗸: 🔍 Regulatory strategy before product development When you map your regulatory pathway first, you design with compliance in mind 📋 Documentation as you go Creating technical documentation alongside development saves months of backtracking 🤝 Early FDA engagement Pre-submission meetings can provide invaluable guidance that prevents costly pivots I recently helped a startup implement these approaches, cutting their submission preparation time by 40% and securing first-round approval! The MedTech landscape is only getting more complex. The companies that thrive will be those that make regulatory excellence a competitive advantage, not a checkbox. What's your biggest regulatory challenge right now? I'd love to hear what's keeping you up at night?

Is RWE + RCT As Close to A ‘Perfect Marraige’ As One Can Get?? The Indispensable Value of Hybrid Data in Advancing Psychiatry Combining Randomized Controlled Trial (RCT) data with Real-World Evidence (RWE) is not just beneficial—it's absolutely crucial for truly advancing psychiatric treatment and achieving personalized medicine. RCTs have long been the gold standard, providing high internal validity to establish the efficacy of an intervention. They isolate variables, control for confounders, and demonstrate causality under meticulously managed conditions. This is essential for drug approval and initial clinical guidelines. However, they operate in a highly selective environment. The patient populations in RCTs are often homogeneous, excluding individuals with common comorbidities, polypharmacy use, or greater severity, which are the very characteristics of patients seen daily in clinical practice. This is where RWE steps in. Drawn from diverse sources like electronic health records (EHRs), patient registries, insurance claims data, and even passive monitoring via wearables, RWE provides a robust measure of effectiveness and safety in the wild. It reflects the true patient journey: complex medication adherence patterns, varied clinician interpretations, and the impact of social determinants of health. Bridging the Efficacy-Effectiveness Gap In psychiatry, where conditions are inherently heterogeneous (e.g., depression, bipolar disorder) and treatment responses are highly variable, this hybrid approach is transformative. Integrating RCT data (RWE) with RWE (RCT) allows us to: * Understand Treatment Response Variability: We can use RWE to identify clinical and genetic subgroups that respond optimally to an intervention initially proven efficacious in an RCT, moving us closer to truly personalized care. * Assess Long-Term Safety and Tolerability: While RCTs typically run for a fixed duration, RWE offers invaluable, longitudinal data on adverse event profiles and persistence of treatment effects over months or years, which is critical for chronic mental health conditions. * Validate and Generalize Findings: RWE validates RCT findings in broader, more representative populations, ensuring that a treatment deemed "effective" is actually helping the majority of patients outside of a research setting. Let's champion this data synergy to move beyond one-size-fits-all care and build smarter, more patient-centered mental health solutions. This collaborative approach between researchers, clinicians, and data scientists will ultimately translate to better outcomes for patients facing complex psychiatric disorders.

💡 FDA recently released 89 previously unpublished complete response letters (CRLs) issued from 2024 to the present associated with pending or withdrawn applications Major causes for CRLs 📊 are: 1️⃣ Manufacturing & Facility Inspection Deficiencies: - FDA inspections found objectionable conditions at facilities (e.g., contamination risks, GMP violations) - Applications cannot proceed until deficiencies are corrected and re-inspected.   2️⃣ Product Quality / Chemistry, Manufacturing, and Controls (CMC) Deficiencies: - Repeated concerns with stability failures, out-of-specification (OOS) results, and inadequate justification of shelf life - Issues with extractables/leachables, comparability studies, and incomplete testing (e.g., missing data for particulate matter or protein concentration) - FDA often deemed CMC data inadequate to support approval   3️⃣ Inadequate Labeling and Prescribing Information: - FDA frequently flagged non-compliant draft labeling - Examples include: > Use of error-prone symbols/abbreviations that could cause misinterpretation > Failure to meet Physician Labeling Rule (PLR) or Pregnancy & Lactation Labeling requirements > Missing or outdated information in structured product labeling (SPL) format   4️⃣ Data Integrity, Inconsistencies, and Missing Data: - Discrepancies between reports (e.g., potency results across multiple submissions didn’t match) - Missing stability or microbiology data (e.g., skipped timepoints, absent endotoxin/appearance testing) - FDA requested clarification and new analyses before considering approval.   5️⃣ Clinical and Safety Update Deficiencies: - FDA required updated safety data across all trials, including new adverse event information - In some cases, additional clinical pharmacology studies were requested if formulation or device changes were needed - Without these, the risk-benefit profile could not be adequately assessed.   #Innovation #LifeSciences #ICH #QualityByDesign Adi Naidu Guillaume Kerboul 💡 🌍 🤲 John McCarthy Stephanie Balme Mahaut Lambert Source here: https://lnkd.in/ev8dJjpq

FDA just raised the bar for CAR-T approvals. That creates space for different approaches. The agency now requires randomized superiority trials for CAR-T therapies, moving away from single-arm studies. This affects Bristol Myers Squibb, Gilead, and others pursuing new indications or earlier lines of treatment. The shift adds years and significant cost to development timelines. Companies need head-to-head trials against standard of care, larger patient populations, and longer follow-up periods. But here's what I'm watching: this policy change mostly impacts CAR-T programs. While those developers navigate expensive comparative trials in solid tumors where penetration remains a challenge, alternative cell therapy approaches face a different calculus. The FDA's demand for superior efficacy data signals something important. It validates that the standard of care in hard-to-treat solid tumors needs better options, particularly where the blood-brain barrier and tumor penetration create fundamental biological obstacles. For companies working on mechanisms that address those penetration challenges directly, the competitive landscape just shifted. Established players will be occupied with multi-year trials while newer platforms advance through earlier development stages. The regulatory bar went up. But it didn't go up uniformly across all cell therapy modalities.

The FDA approved a drug for a new disease without requiring a clinical trial! Tacrolimus, initially used off-label for lung transplant rejection, proved so effective that once the data was analyzed, the FDA approved it for this new indication. This highlights the power of real-world evidence analysis, a strategy we embrace at Every Cure. By leveraging patient-level data., we can uncover which drugs are actually working and identify opportunities to expand their use to even more patients. This approach is not only faster and less expensive than traditional clinical trials but also a game-changer in getting lifesaving treatments to people worldwide. #raredisease #pharma #drugdevelopment

A founder recently told me they'd just completed Phase 2. FDA loved the endpoint. Clinical team was celebrating. I asked: "Have you talked to a payer consultant about that endpoint?" They hadn't. Here's the trap: The FDA approves drugs based on clinical meaningfulness. Payers reimburse drugs based on economic value and real-world applicability. These are not the same thing. A biomarker endpoint that satisfies the FDA can leave you with a label payers won't cover without a five-year outcomes study. A functional endpoint that looks "soft" clinically can be the only thing a payer actually cares about. I've watched founders celebrate FDA feedback on their Phase 2 design—then get eviscerated in pharma commercial diligence because the endpoint won't support the reimbursement strategy they need. The time to pressure-test your endpoint for commercial viability is before you dose the first patient. Not after you've spent $40M proving something payers won't pay for. Your clinical team is designing for regulatory approval. Your commercial team doesn't exist yet. That gap is expensive. #RareDisease #Biotech #ClinicalTrials